All In Biotech

Drug Trial Radar · NCT05280314

Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Selected Resectable Tumors

Last checked: Nov 20, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Dec 21, 2023

Primary completion

Apr 30, 2025

Study completion Jan 2027

Sponsor

Lead sponsor
IO BiotechIndustry
Sponsor type
Industry
Collaborators
Theradex; Almac; Merck Sharp & Dohme LLC
First posted
Mar 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.

Conditions

  • Melanoma
  • Squamous Cell Carcinoma of Head and Neck

Interventions

  • IO102-IO103Drug

    IO102-IO103 is a combination of an indoleamine 2,3-dioxygenase 1 (IDO1) peptide (IO102) and a programmed death-ligand 1 (PD-L1) peptide (IO103), emulsified with an adjuvant (Montanide ISA 51 VG).

  • Pembrolizumab KEYTRUDA®Drug

    Pembrolizumab KEYTRUDA® administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major pathologic responseTime frame: Observed in the resected tumor tissue after neoadjuvant treatment at surgery

Locations

15 sites in 6 countries. Site status is shown where the registry gives one.

  • Yale

    New Haven, Connecticut · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Massey Cancer Center

    Richmond, Virginia · Recruiting

  • Melanoma Institute Australia The Uiniversity of Sydney, and Royal North Shore Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Aarhus University Hospital

    Aarhus, Denmark · Recruiting

  • Copenhagen University Hospital Herlev

    Copenhagen, Denmark · Recruiting

  • CHRU Lille

    Lille, France · Recruiting

  • Hôpital Ambroise-Paré

    Paris, France · Recruiting

  • Institut Gustave Roussy

    Paris, France · Recruiting

  • Universitätsklinikum Essen & Research Alliance Ruhr

    Essen, Germany · Recruiting

  • Universität Heidelberg, Medizinische Fakultät

    Heidelberg, Germany · Recruiting

  • Hospital Universitario Quirón Dexeus

    Barcelona, Spain · Recruiting

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain · Recruiting

  • Hospital Clínico Universitario de Valencia -INCLIVA

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.